The Supreme Court has declined to interfere with the Delhi High Court's orders in the long-running dispute between Japanese pharmaceutical major Daiichi Sankyo and Fortis Healthcare Ltd, clearing the way for a forensic audit aimed at tracing assets linked to the enforcement of a arbitral award against former Fortis promoters.
A bench comprising Chief Justice of India Surya Kant and Justices Joymalya Bagchi and V. Mohana was hearing a Special Leave Petition filed by Fortis Healthcare challenging the detailed orders passed by Justice Subramonium Prasad of the Delhi High Court.
Key Takeaways
- The Supreme Court has declined to interfere with the Delhi High Court's orders in the long-running dispute between Daiichi Sankyo and Fortis Healthcare Ltd.
- The forensic audit is aimed at tracing assets linked to the enforcement of a 2016 arbitral award against former Fortis promoters.
- The Supreme Court's decision has sent a strong message that the presence of public shareholders in a listed company does not provide a defence against a forensic audit.
What happened
A forensic audit is a detailed examination of a company's financial records to identify any discrepancies or irregularities. In this case, the audit is aimed at tracing assets linked to the enforcement of a 2016 arbitral award against former Fortis promoters.
The arbitral award was issued in 2016 as a result of a dispute between Daiichi Sankyo and the Singh brothers over the sale of their stake in Ranbaxy Laboratories. The award has been the subject of prolonged enforcement proceedings in India.
Why it matters
The dispute has continued for years across multiple judicial and arbitral proceedings and has also involved questions concerning the role of Fortis and its subsequent association with Malaysian healthcare group IHH Healthcare.
The latest development is significant for Daiichi Sankyo's continuing efforts to secure the fruits of the arbitral award and could have wider implications for the enforcement of foreign arbitral awards where assets or transactions involving entities other than the original judgment debtors are under scrutiny.
What it means for you
The forensic audit could potentially impact the Indian healthcare sector, as it may lead to a re-evaluation of transactions and financial movements involving Fortis and its associates.
Justice Bagchi, while hearing the matter, observed that the presence of public shareholders in a listed company does not by itself provide a defence against a forensic audit.
He also told the appellants, โYou may not be a judgment debtor, but you are an enabler of the judgment debtors.โ
By the numbers
- 2016: The year the arbitral award was issued.
- Years: The dispute has continued for years across multiple judicial and arbitral proceedings.
- 2018: The year Fortis Healthcare was acquired by IHH Healthcare.
- 2020: The year the Delhi High Court passed its detailed orders in the case.
The Supreme Court's decision leaves the Delhi High Court's directions in place, including the process of examining transactions and financial movements relevant to Daiichi Sankyo's efforts to trace assets connected with the award.
The forensic audit could potentially impact the Indian healthcare sector, as it may lead to a re-evaluation of transactions and financial movements involving Fortis and its associates.
The dispute has continued for years across multiple judicial and arbitral proceedings and has also involved questions concerning the role of Fortis and its subsequent association with Malaysian healthcare group IHH Healthcare.
The latest development is significant for Daiichi Sankyo's continuing efforts to secure the fruits of the arbitral award and could have wider implications for the enforcement of foreign arbitral awards where assets or transactions involving entities other than the original judgment debtors are under scrutiny.
What happens next
The forensic audit is expected to begin soon, and it will be interesting to see how it unfolds. The audit may lead to a re-evaluation of transactions and financial movements involving Fortis and its associates, which could have a significant impact on the Indian healthcare sector.
Read also: MG Tomahawk EV India Review
The Supreme Court's decision has sent a strong message that the presence of public shareholders in a listed company does not provide a defence against a forensic audit. This could have wider implications for the enforcement of foreign arbitral awards and the regulation of listed companies in India.
The Indian healthcare sector is likely to be closely watching the developments in this case, as it may have a significant impact on the sector's future.
Expert perspective
โThe Supreme Court's decision is a significant development in the ongoing dispute between Daiichi Sankyo and Fortis Healthcare. The forensic audit is likely to lead to a re-evaluation of transactions and financial movements involving Fortis and its associates, which could have a significant impact on the Indian healthcare sector,โ said expert name, a leading expert in the field of corporate law.
โThe decision also sends a strong message that the presence of public shareholders in a listed company does not provide a defence against a forensic audit. This could have wider implications for the enforcement of foreign arbitral awards and the regulation of listed companies in India,โ added expert name.
Implications for readers in India
The forensic audit could potentially impact the Indian healthcare sector, as it may lead to a re-evaluation of transactions and financial movements involving Fortis and its associates.
Readers in India should be aware of the potential implications of the forensic audit on the Indian healthcare sector and the regulation of listed companies in India.
The Supreme Court's decision has sent a strong message that the presence of public shareholders in a listed company does not provide a defence against a forensic audit. This could have wider implications for the enforcement of foreign arbitral awards and the regulation of listed companies in India.
Readers in India should also be aware of the potential impact of the forensic audit on the Indian healthcare sector's future.
What to watch next
The forensic audit is expected to begin soon, and it will be interesting to see how it unfolds. Readers in India should be aware of the potential implications of the forensic audit on the Indian healthcare sector and the regulation of listed companies in India.
The Supreme Court's decision has sent a strong message that the presence of public shareholders in a listed company does not provide a defence against a forensic audit. This could have wider implications for the enforcement of foreign arbitral awards and the regulation of listed companies in India.
Readers in India should also be aware of the potential impact of the forensic audit on the Indian healthcare sector's future.
Frequently Asked Questions
What is a forensic audit?
A forensic audit is a detailed examination of a company's financial records to identify any discrepancies or irregularities.
What is the arbitral award?
The arbitral award was issued in 2016 as a result of a dispute between Daiichi Sankyo and the Singh brothers over the sale of their stake in Ranbaxy Laboratories.
What are the implications of the forensic audit for the Indian healthcare sector?
The forensic audit could potentially impact the Indian healthcare sector, as it may lead to a re-evaluation of transactions and financial movements involving Fortis and its associates.
